Cancer Management and Research最新文献

{"title":"Efficacy of Bronchial Artery Infusion/Chemoembolization Combined with Platinum-Based Chemotherapy and PD-1 Inhibitor in Initially Unresectable Stage III Non-Small Cell Lung Cancer.","authors":"Xiaoying Quan, Lei Lei, Xiaoyan Chen, Xiaoli Jia, Chunzhi Wu, Bin Ye, Qiyue Huang, Min Luo, Ning Wang, Jiayang Yu, Lifu Feng","doi":"10.2147/CMAR.S589356","DOIUrl":"https://doi.org/10.2147/CMAR.S589356","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the efficacy of bronchial arterial infusion/bronchial arterial chemoembolization (BAI/BACE) combined with platinum-based doublet chemotherapy and PD-1 inhibitor in patients with initially unresectable stage III non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>This retrospective study analyzed 42 patients with initially unresectable stage III NSCLC treated between September 2020 and March 2025. Patients were divided into the BAI group (n=20), which received BAI/BACE combined with platinum-based doublet chemotherapy and PD-1 inhibitor, and the Non-BAI group (n=22), which received platinum-based doublet chemotherapy and PD-1 inhibitor alone. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between the groups. Patients were further categorized into the surgery group (n=19) and the Non-surgery group (n=23) whether they underwent resection after induction therapy, and their survival outcomes were compared.</p><p><strong>Results: </strong>The overall ORR was 64.3%. The ORR of the BAI group was significantly higher than the Non-BAI group (80.0% vs 50.0%, <i>P=</i>0.043). Survival analysis showed that the 2-year PFS and OS rates for the entire cohort were 41.2% and 64.3%, respectively. The BAI group had significantly better 2-year PFS (52.8% vs 29.1%, <i>P=</i>0.032) and OS (78.3% vs 51.7%, <i>P=</i>0.022) than the Non-BAI group. Treatment-related adverse events were predominantly grade I-II, with no significant differences between groups. Following induction therapy, 64.3% (27/42) of patients achieved successful downstaging, and the surgical conversion rate was 45.2% (19/42). The pathological complete response (pCR) and major pathological response (MPR) rates were 10.5% (2/19) and 36.8% (7/19), respectively. Furthermore, the surgery group showed significantly better 2-year PFS (64.8% vs. 20.7%, <i>P</i>=0.001) and OS (93.8% vs. 39.6%, <i>P</i>=0.001) than the Non-surgery group.</p><p><strong>Conclusion: </strong>BAI/BACE combined with immunochemotherapy demonstrates promising efficacy and a manageable safety profile in the conversion therapy of initially unresectable stage III NSCLC. Successful downstaging followed by surgery is associated with improved survival outcomes. Nevertheless, given the small sample size and retrospective design, these findings should be considered exploratory and warrant validation in larger prospective studies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"589356"},"PeriodicalIF":2.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13142690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Relationship Between Netrin-1 Staining and Neoadjuvant Treatment Response in HER2-Positive Locally Advanced Breast Cancer [Corrigendum].","authors":"","doi":"10.2147/CMAR.S620903","DOIUrl":"https://doi.org/10.2147/CMAR.S620903","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/CMAR.S551516.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"620903"},"PeriodicalIF":2.6,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13142168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial Chemoembolization Combined with Regorafenib and PD-1 Inhibitor as Second-Line Therapy for Unresectable Hepatocellular Carcinoma.","authors":"Di Wang, Wei Zhang, Xudong Gao, Huifang Kong, Huixin Zhang, Jiagan Huang, Meng Zhang, Xiujuan Chang, Zhen Zeng","doi":"10.2147/CMAR.S578610","DOIUrl":"https://doi.org/10.2147/CMAR.S578610","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of transarterial chemoembolization (TACE) plus regorafenib and PD-1 inhibitor (T-R-P) versus regorafenib plus PD-1 inhibitor (R-P) as the second-line treatment for unresectable hepatocellular carcinoma (uHCC).</p><p><strong>Methods: </strong>In this retrospective, single-center cohort study, 130 uHCC patients who received second-line therapy between February 2020 and July 2024 were enrolled. Among the 130 enrolled patients, 69 received T-R-P and 61 received R-P. Propensity score matching (PSM) and inverse probability treatment weighting (IPTW) were used to minimize confounding factors. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). Multivariate Cox regression analysis was used to identify prognostic factors. Subgroup analyses were conducted to assess the treatment benefits in specific patient populations.</p><p><strong>Results: </strong>After PSM, the T-R-P regimen showed significantly improved OS (14.3 vs 8.1 months) and PFS (8.4 vs 4.3 months) compared to the R-P regimen (P < 0.001). According to mRECIST, ORR (56.5% vs 15.2%) and DCR (69.6% vs 37.0%) were also significantly higher with the T-R-P regimen. Multivariate Cox regression analysis identified the T-R-P regimen as an independent protective factor for both OS (hazard ratio [HR] = 0.33, P < 0.001) and PFS (HR = 0.39, P < 0.001). These consistent survival benefits in the T-R-P regimen were maintained in both the unmatched cohort and after IPTW. Subgroup analyses further confirmed the consistent survival benefits of the T-R-P regimen across the most predefined patient subgroups. No treatment-related deaths occurred during the study period.</p><p><strong>Conclusion: </strong>After PSM, the T-R-P regimen continued to demonstrate statistically significant and clinically meaningful improvements in both OS and PFS, coupled with a manageable safety profile, compared to the R-P regimen in patients with uHCC. These findings provide a rationale for considering the T-R-P regimen as a potential second-line treatment option.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"578610"},"PeriodicalIF":2.6,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Characterisations and the Association with Clinical Factors in <i>RET</i> Fusion-Positive NSCLC: A Retrospective Study of the Single Center Cohort.","authors":"Xiang Li, Peiyan Zhao, Heran Cui, Tingting Zhang, Wenyu Sun, Hui Li","doi":"10.2147/CMAR.S579561","DOIUrl":"https://doi.org/10.2147/CMAR.S579561","url":null,"abstract":"<p><strong>Background: </strong><i>RET</i> fusion is a pathogenic driver factor in lung cancer patients. Currently, the conclusions on the clinical factors of <i>RET</i> fusion in NSCLC are inconsistent.</p><p><strong>Methods: </strong>From 2018 to 2024, 6,204 lung cancer patients received next‑generation sequencing (NGS) testing, among whom 102 were confirmed to be positive for <i>RET</i> fusion. The clinical and molecular characteristics of these patients were analyzed and compared.</p><p><strong>Results: </strong>In this cohort, the prevalence of <i>RET</i> fusions was 1.6% (102/6204). Most patients were female (54.90%), <60 years (53.92%), non-smokers (72.55%), with advanced-stage (68.63%), metastatic (69.61%, mostly lymph nodes), adenocarcinoma (98.04%), and PS 0-1 (90.20%). The most common fusion partners of <i>RET</i> were <i>KIF5B</i> (50.00%, 51/102) and <i>CCDC6</i> (22.55%, 23/102).; noval partners including <i>C16orf95, CARNMT1-AS1, CXCL12, MTUS1</i> and <i>MYRFL</i> were identified. Common fusion partners were associated with age (P=0.023) and PS score (P=0.040), with higher rates of <i>RET</i> fusion in patients <60 years of age and those with a PS score of 0-1 (81.80% and 76.10%, respectively. <i>TP53</i> represented the most frequent concomitant alteration in <i>RET</i> fusions, occurring at a rate of 14.71% (15/102).</p><p><strong>Conclusion: </strong>The new discoveries of <i>RET</i> fusion partners were founded in NSCLC. In addition, the broad-panel NGS is essential for NSCLC patients to catch these rare/novel fusions that PCR or small panels might miss.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"579561"},"PeriodicalIF":2.6,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant Chemotherapy on the Prognosis in Elderly Patients with Stage II and III Colorectal Cancer: A Retrospective Multicenter Study.","authors":"Eui Myung Kim, Il Tae Son, Byung Chun Kim, Jun Ho Park, Jin Won Lee, Jong Wan Kim","doi":"10.2147/CMAR.S589756","DOIUrl":"https://doi.org/10.2147/CMAR.S589756","url":null,"abstract":"<p><strong>Purpose: </strong>The objective of this retrospective multicenter study was to evaluate the efficacy of adjuvant chemotherapy (adCTx) following curative resection in patients aged ≥70 years with colorectal cancer (CRC) and to compare the outcomes of monotherapy versus combination chemotherapy.</p><p><strong>Methods: </strong>Data from 1183 patients with stage II or III CRC who underwent surgery at five Hallym University-affiliated hospitals in Korea between 2012 and 2022 were retrospectively analyzed. Patients were divided into two groups based on adjuvant chemotherapy status (adCTx (+) vs adCTx (-)). Those receiving adCTx were further stratified into 5-fluorouracil (5-FU) monotherapy or 5-FU plus oxaliplatin combination therapy. Multivariable Cox regression was used to estimate adjusted hazard ratios (HRs) for overall survival (OS) and recurrence-free survival (RFS).</p><p><strong>Results: </strong>Of the 1183 patients, 555 received adCTx and 628 did not. Patients in the adCTx (+) group showed significantly better 5-year OS (88.6% vs 75.7%, P < 0.001) and RFS (66.5% vs 58.6%, P < 0.001). In multivariable analysis, adCTx was independently associated with improved OS (HR 0.33, 95% CI 0.23-0.48, P < 0.001) and RFS (HR 0.59, 95% CI 0.47-0.76, P < 0.001). Among patients receiving chemotherapy, there was no significant difference in OS or RFS between monotherapy and combination therapy. In stage II patients with high-risk factors, adCTx (+) was associated with better OS (P = 0.002) and RFS (P = 0.006), but the number of agents did not provide additional benefit.</p><p><strong>Conclusion: </strong>In this study of patients aged ≥70 years with stage II or III CRC, adjuvant chemotherapy was associated with improved OS and RFS. No significant differences in oncologic outcomes were observed between monotherapy and combination therapy. These findings suggest a potential benefit of adjuvant chemotherapy in selected elderly patients; however, prospective randomized studies are needed to confirm these results.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"589756"},"PeriodicalIF":2.6,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Fusion of 3D CT and Pathological Images for Gastric Cancer Recurrence Prediction.","authors":"Longjun Cao, Mengxin Tian, Jia Li, Zhongtao Chen, Xuefei Wang, Su Zhong, Guoqing Wu, Zhaoqing Tang, Jinhua Yu","doi":"10.2147/CMAR.S563640","DOIUrl":"https://doi.org/10.2147/CMAR.S563640","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer recurrence severely impacts postoperative outcomes, and accurate prediction is crucial for personalized management. 3D CT images (macroscopic lesion context) and Whole Slide Images (WSIs, microscopic histopathological details) offer complementary information, but effective fusion is hindered by feature dimensionality disparity and lack of robust integration strategies. Existing models show suboptimal performance due to inadequate multimodal fusion, resulting in unreliable risk assessments that cannot be clinically applied for personalized therapy.</p><p><strong>Aim: </strong>To preoperatively identify high-risk patients and enable personalized postoperative follow-up and treatment stratification to assist clinicians, this study adopts a fusion strategy combining multi-stage attention and co-attention mechanisms to achieve efficient integration of Whole Slide Images (WSIs) and CT images, thereby providing an accurate, robust and generalizable solution for gastric cancer recurrence prediction.</p><p><strong>Methods: </strong>This retrospective multi-center study included three datasets: a primary cohort (646 patients, Zhongshan Hospital) and two independent test sets (160 patients, Zhongshan Hospital Xiamen Branch; 140 patients, Taicang TCM Hospital). CT features were extracted using DSMAGNet integrated with the iSAFF module and GateNetwork, while Whole Slide Image (WSI) features were derived via multi-stage attention-based dimensionality reduction (MSAT). Finally, multimodal fusion of the two types of features was accomplished through a co-attention mechanism.</p><p><strong>Results: </strong>The framework achieved an AUC of 83.4% on the primary dataset, outperforming 11 comparative methods by up to 4.2%. On external test sets, it showed superior performance with AUC improvements of 4.63% and 3.91% vs. the next-best methods. Ablation studies confirmed the effectiveness of DSMAGNet and MSAT.</p><p><strong>Conclusion: </strong>The multimodal framework enables accurate, interpretable, and generalizable gastric cancer recurrence prediction by integrating WSI and CT images. It aids preoperative identification of high-risk patients, supporting personalized postoperative follow-up and treatment stratification to improve long-term outcomes.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"563640"},"PeriodicalIF":2.6,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus and Secondary Deep Venous Thrombosis: A Case Report.","authors":"Junde Liu, Kai He, Zhonghua Luo, Jian Xiong, Yunbao Cao, Weiling Yin, Kun Yue, Rui Hua","doi":"10.2147/CMAR.S584342","DOIUrl":"https://doi.org/10.2147/CMAR.S584342","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVCTT) remains a major clinical challenge. Venous outflow obstruction from the thrombus can precipitate severe lower-extremity edema and secondary deep vein thrombosis (DVT). Current guidelines do not recommend routine placement of inferior vena cava filters (IVCFs) in this setting because progressive tumor thrombus may increase the risk of filter migration and can worsen thrombosis. Here, we report a 52-year-old man with right RCC and a level II IVCTT (Mayo classification) complicated by extensive iliofemoral DVT. He was treated using a combined interventional strategy that included endoluminal brachytherapy with long iodine-125 (^125I) seed strands, catheter-directed thrombolysis (CDT), and renal artery embolization (RAE). After treatment, inferior vena cava outflow improved markedly, and swelling of the lower limbs and scrotum resolved. Follow-up imaging demonstrated substantial regression of the tumor thrombus and a reduced renal tumor burden. To overcome the limitations of inadequate intraluminal dose coverage and the technical difficulty of safely implanting seeds directly within a mobile tumor thrombus, we used two self-designed long ^125I seed strands that were securely anchored at the jugular venous access region to deliver continuous, localized irradiation to the IVCTT. CDT and RAE were applied to further reduce thrombus and tumor volume and were associated with a favorable clinical response in this patient. The patient remained alive without disease progression for more than 39 months from diagnosis. This case illustrates the potential role of a multimodal interventional approach for simultaneous control of IVCTT and venous thrombosis and highlights the feasibility of endoluminal brachytherapy using radioactive seed strands as a strategy to manage complex RCC with IVCTT.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"584342"},"PeriodicalIF":2.6,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Thermosensitive Hydrogel Combined with Pirarubicin via TACE for Hepatocellular Carcinoma: A Pilot Study.","authors":"Chang Liu, Qihui Hu, Baoyong Zhou, Xiang Zhang, Rui Tao","doi":"10.2147/CMAR.S593223","DOIUrl":"https://doi.org/10.2147/CMAR.S593223","url":null,"abstract":"<p><strong>Aim: </strong>This pilot study aims to evaluate the technical feasibility, safety profile, and preliminary efficacy of Tepoxin, a thermosensitive hydrogel, combined with pirarubicin via transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC), providing foundational data for future larger-scale trials.</p><p><strong>Methods: </strong>This is a single-center, retrospective, single-arm pilot study including 7 HCC patients who received Tepoxin combined with pirarubicin TACE between 2023 and 2025. Inclusion criteria were: confirmed HCC by imaging or pathology, Child-Pugh A-B liver function, ECOG performance status ≤ 2, and no severe comorbidities. The procedure involved selective hepatic artery catheterization to deliver pirarubicin-loaded hydrogel for embolization. Primary endpoints were procedure success rate, adverse events, tumor response (evaluated by changes in the maximum tumor diameter and mRECIST criteria for PR/SD/PD), and disease control rate (DCR). Follow-up was conducted for at least 4-6 weeks for preliminary imaging assessment.</p><p><strong>Results: </strong>All 7 patients completed the procedure without failure or discontinuation. Tumor response was assessable in all patients: 2 achieved partial response (PR), 4 had stable disease (SD), and 1 had progression (PD). The objective response rate (ORR) was 28.6% (2/7), and the disease control rate (DCR) was 85.7% (6/7). Adverse events were mild, including fever, abdominal pain, and nausea/vomiting (grade 1-2), with no severe toxicity (grade ≥3) or treatment interruption. Mild liver function fluctuations were observed in some patients, which recovered to baseline.</p><p><strong>Conclusion: </strong>Tepoxin combined with pirarubicin TACE is technically feasible and well-tolerated in HCC patients, showing early anti-tumor activity. Larger, well-designed studies are needed to confirm its efficacy and safety.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"593223"},"PeriodicalIF":2.6,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13118685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitators and Barriers to Cervical Cancer Screening Among Women in a Rural District of Northeastern Uganda, a Qualitative Study.","authors":"Ibra Mutyaba, Hellen Akurut, Racheal Nabaasa, Jonathan Limo, Emmanuel Okupa, Christine Acari Omuke, Ronald Opito","doi":"10.2147/CMAR.S598738","DOIUrl":"https://doi.org/10.2147/CMAR.S598738","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer screening in Uganda has remained relatively low, with fewer than one in 10 of eligible women screened, despite the availability of cervical cancer screening services in most health facilities. The barriers and facilitators of cervical cancer screening in remote rural settings of Northeastern Uganda like Ngora are not yet well understood. This study therefore aimed to assess the barriers and facilitators to cervical cancer screening among women of reproductive age in a remote rural district Ngora, Northeastern Uganda.</p><p><strong>Methods: </strong>This study employed a qualitative approach to gather in-depth insight into the barriers and facilitators of cervical cancer screening. We conducted six focused group discussions (FGDs) (4 females and 2 males) with the community members and nine key informant interviews (KIIs) with the health workers in Ngora district. The participants for FGDs were chosen through convenient sampling while those for KIIs were chosen through purposive sampling methods. The interviews were audio-recorded and subsequently transcribed for analysis. Data was analyzed using thematic analysis techniques to identify significant patterns and themes related to cervical cancer screening behaviors, while inductive coding was conducted to identify codes and create meaning around the texts.</p><p><strong>Results: </strong>The facilitators of cervical cancer screening were active community sensitization, availability of screening services at designated facilities, supportive national policies, and integration with other health services, while the barriers included myths and misconceptions about cervical cancer screening, stock-outs of essential commodities for screening, long distances to the health facilities, limited human resources, and informal costs charged by the health facilities.</p><p><strong>Conclusion: </strong>Improving cervical cancer screening uptake requires a multi-pronged approach that strengthens health systems, addresses myths and misinformation, reduces financial and logistical burdens, and mobilizes community support.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"598738"},"PeriodicalIF":2.6,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13118634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncolytic Vaccinia Virus-Engineered EVs Convert Tumor-Promoting Macrophages into Anti-Tumor Effectors.","authors":"Liqiong Chen, Luyi Ye, Liuqian Bao, Junwei Wang, Mingming Tan","doi":"10.2147/CMAR.S589766","DOIUrl":"https://doi.org/10.2147/CMAR.S589766","url":null,"abstract":"<p><strong>Introduction: </strong>Extracellular vesicles (EVs) play a critical role in shaping the tumor immune microenvironment (TME) by mediating intercellular communication and transferring oncogenic proteins, microRNAs, and immunosuppressive molecules. Tumor-derived EVs (TDEVs) typically promote immune evasion by inducing M2 macrophage polarization, suppressing cytotoxic T-cell activity, and enhancing angiogenesis. Recent evidence suggests that oncolytic viruses (OVs) can reprogram EV secretion, generating OV-derived EVs (OV-EVs) with immunostimulatory properties capable of activating antitumor immune responses.</p><p><strong>Methods: </strong>In this study, we investigated how infection with oncolytic vaccinia virus (OVV) alters the EV secretion profile of colon cancer cells. EVs derived from OVV-infected tumor cells were isolated and characterized, and their effects on macrophage polarization were evaluated using in vitro assays.</p><p><strong>Results: </strong>Our results demonstrate that OVV infection significantly alters the composition and immunological properties of tumor-derived EVs. OV-EVs were enriched with pathogen-associated and damage-associated molecular patterns (PAMPs/DAMPs), which promoted macrophage reprogramming toward a pro-inflammatory M1 phenotype and enhanced immune activation associated with antitumor responses.</p><p><strong>Discussion: </strong>These findings indicate that OVV-induced EVs can reshape the tumor immune microenvironment by modulating macrophage polarization. This study provides new insights into the EV-mediated mechanisms of oncolytic virotherapy and highlights the potential of OV-derived EVs as a novel strategy for EV-based cancer immunotherapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"589766"},"PeriodicalIF":2.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}